TORONTO, Feb. 05, 2019 (GLOBE NEWSWIRE) -- Datametrex AI Limited (TSXV:DM) (the
“Company” or “Datametrex”) is pleased to announce its agreement to partner with EMPOWER CLINICS
INC. (CSE: EPW) (“Empower”) through its subsidiary Canntop AI Inc. (“Canntop”)
on the creation of a pilot program (“Pilot”) using Artificial Intelligence (“AI”) to analyze and
gain insights about Empower patient data, physician treatment recommendations and overall long-term efficacy of patient care. This
is to identify improvements and efficacy in long-term patient care.
Empower intends to use Canntop’s AI platform to gain actionable insights on how consumer social data is
generating nationwide interest in CBD based products, alternative pain management options and the use of cannabis-based
therapies.
The initial pilot will utilize Empower patient data in a HIPAA compliant manner, to determine if normalized data
can be generated using Datametrex AI solutions to understand how patient care and efficacy of physician guided treatment
recommendations are positively impacting serious qualifying conditions of patients.
“We believe using AI tools to analyze the substantial amounts of data in the Empower database and the additional
data from the recently announced proposed Sun Valley acquisition can make Empower a data science leader in the Cannabis industry,”
said Steven McAuley, Empower’s Chairman & CEO. He further states, “The outcomes of our AI efforts with Datametrex are definitely
going to position the Company as an educational leader and we plan to collaborate with the industry to ultimately improve patient
care.”
“Datametrex has already utilized its Nexalogy AI solution for Health Canada studies in the Cannabis sector to
understand consumer usage and patterns based on massive social insights generated through social media channels,” said Jeffrey
Stevens, Datametrex President & COO. “We believe an AI pilot with Empower has the potential to provide disruptive insights that
alternative care options can provide people around the world.”
ABOUT EMPOWER
Empower is undertaking new growth initiatives to be positioned as a vertically integrated diverse health and
wellness company with an expanding network of physician-staffed clinics, a diverse CBD product strategy and a leader in
hemp-derived CBD extraction, research and development. Treatment solutions are focused on education, data and efficacy in
combination with other modalities to support patients with serious qualifying conditions, such as chronic pain, PTSD, sleep
disorders, opioid dependency, epilepsy and more. It is expected that Empower's proprietary product line “Sollievo” will offer
patients a variety of delivery methods of doctor recommended cannabidiol (CBD) based product options in its clinics, online and at
major retailers. With over 120,000 patients, an expanding clinic footprint, a focus on new technologies, including tele-medicine
and an expanded product development strategy, Empower is ready to capitalize on the explosive growth expectations in the United
States after the passing of US$867 billion Agriculture Improvement Act (the Farm Bill).
About Datametrex
Datametrex AI Limited is a technology focused company with exposure to Artificial Intelligence and Machine
Learning through its wholly owned subsidiaries, Nexalogy (www.nexalogy.com) and Canntop AI (www.canntop.com) and Implementing
Blockchain technology for secure Data Transfers through its investee company, Graph Blockchain (www.graphblockchain.com).
Additional information on Datametrex is available at: www.datametrex.com
For further information, please contact:
Jeffrey Stevens – President & COO
Phone: (647) 400-8494
Email: jstevens@datametrex.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains "forward-looking information" within the meaning of applicable securities laws.
All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some
cases, forward-looking information can be identified by words or phrases such as "may", "will", "expect", "likely", "should",
"would", "plan", "anticipate", "intend", "potential", "proposed", "estimate", "believe" or the negative of these terms, or other
similar words, expressions and grammatical variations thereof, or statements that certain events or conditions "may" or "will"
happen, or by discussions of strategy.
By their nature, forward-looking information is subject to inherent risks and uncertainties that may be general
or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not
prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved.
A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ
materially from the forward-looking information in this press release. Such factors include, without limitation, those discussed in
the Company's current MD&A and Annual Information Form, both of which have been filed on SEDAR and can be accessed at
www.sedar.com.
Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not
to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of
this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking
information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result
of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between
subsequent actual events and such forward-looking information, except as required by applicable law.
